The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

The genetic testing company 23andMe has agreed to pay $30 million to American plaintiffs to settle a lawsuit over a data breach last year that specifically targeted customers of Ashkenazi Jewish ...

23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts. The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...

When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics ...

Users are wondering what’s next — and if their personal data (including their literal DNA) are safe. Here’s what we know.

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year ...

23andMe Holding Co. has introduced Discover23®, a new research platform allowing authorized partners to securely access a vast array of genetic data through a Trusted Research Environment (TRE ...